Using lung ultrasound to guide treatment for acute heart failure
Official title: Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography (IcarUS) : a Randomized Controlled Trial
Run by University Hospital, Geneva · NCT06465498 · Data updated 2026-11-12
This study is testing if using lung ultrasound to guide treatment can help adults with acute heart failure leave the hospital sooner and feel better compared to standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 222 (estimated) |
| Sponsor | University Hospital, Geneva Academic / other |
| Locations | 5 sites (Geneva, Canton of Geneva and 4 other locations) |
| Status | Recruiting |
| Started | October 22, 2024 |
| Main results expected | April 30, 2027 |
| Study ends | April 30, 2027 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT06465498 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who are hospitalized for congestive acute heart failure and have elevated levels of N-terminal pro-brain natriuretic peptide.
✕Probably not a fit
Patients with isolated right heart failure, severe hypotension, or conditions mimicking lung edema may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness of a lung ultrasonography (LUS)-guided decongestion strategy for adults hospitalized with acute heart failure (AHF). It aims to determine if this approach can shorten hospital stays, reduce early readmissions, and improve patients' symptoms and quality of life compared to traditional physical examination methods. The study will be conducted as a multicenter, blinded, randomized controlled trial involving 222 participants, who will be assigned to either the LUS-guided strategy or standard care within 48 hours of hospital admission. The primary outcome will measure the number of days spent alive outside the hospital within 40 days of inclusion.
Why it matters
Potential benefit: If successful, this approach could lead to improved patient outcomes and reduced healthcare costs for those suffering from acute heart failure.
How similar studies have gone: While lung ultrasonography has shown benefits in chronic heart failure management, this specific application in acute heart failure is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years old * Planned or actual admission to intermediate care units, general internal medical or cardiology wards * Diagnosis of congestive AHF on admission chart (primary or secondary diagnosis) * Raised value of N terminal-pro-brain natriuretic peptide (≥1000 ng/l). Key Exclusion Criteria: * Known isolated right heart failure * Systolic blood pressure \<90 mmHg, mean arterial pressure \<65 mmHg at the moment of inclusion * The following conditions mimicking lung cardiogenic oedema on LUS if known at inclusion and documented: Interstitial lung disease, lung cancer or metastasis, acute respiratory distress syndrome, pulmonary contusion * Known virologically confirmed SARS-CoV-2 pneumonia in the preceding 3 months * Unwillingness to give consent * Subjects who are pregnant or breastfeeding * Hospitalisation for palliative care and probable end-life within 30 days
Where it's running
-
Trois-Chêne Hospital, Geneva Univesity Hospitals
Geneva, Canton of Geneva, Switzerland Recruiting -
Geneva University Hospitals
Geneva, Canton of Geneva, Switzerland Recruiting -
Inselspital, Universitätspital
Bern, Switzerland, Switzerland Recruiting -
Fribourg University Hospital
Fribourg, Switzerland Recruiting -
Ospedale Civico, Ente Ospedaliero Cantonale
Lugano, Switzerland Terminated
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Infusion of furosemide to see if a loading infusion helps remove fluid better in acute heart failure
This study tests whether giving furosemide as a continuous infusion with a loading dose is better at removing excess fluid than giving it as bolus injections in adults with acute heart failure.
-
Characterizing phenotypes of acute heart failure
This project will try to see if heart function measures, imaging features (radiomics), and blood biomarkers can predict outcomes for adults hospitalized with acute heart failure, including cardiogenic shock.
-
Early finerenone treatment for hospitalized adults with acute heart failure and LVEF ≥40%
This trial will test whether starting finerenone early during hospitalization helps adults with acute heart failure who have a left ventricular ejection fraction of 40% or higher.
-
Intensive GDMT optimization for women after heart failure hospitalization
This study tests whether rapidly increasing and closely monitoring heart failure meds in women after hospitalization can reduce death or readmission within a year.
-
Using intra‑abdominal pressure and bedside ultrasound to guide decongestive treatment in heart failure
This trial will test whether using bladder pressure (intra‑abdominal pressure) measurements together with bedside ultrasound to guide IV loop diuretics helps people hospitalized with acute heart failure get rid of excess fluid more effectively than usual care.
-
Investigating heart issues in COPD patients during hospital stays
This study is trying to see if sudden worsening of COPD can cause heart problems in hospitalized patients and how it affects their recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.